Bystander gene activation by a locus control region
2004; Springer Nature; Volume: 23; Issue: 19 Linguagem: Inglês
10.1038/sj.emboj.7600365
ISSN1460-2075
AutoresIsabela Cajiao, Aiwen Zhang, Eung Jae Yoo, Nancy E. Cooke, Stephen A. Liebhaber,
Tópico(s)RNA Research and Splicing
ResumoArticle9 September 2004free access Bystander gene activation by a locus control region Isabela Cajiao Isabela Cajiao Departments of Genetics and Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA Search for more papers by this author Aiwen Zhang Aiwen ZhangPresent address: Ohio State University, Columbus, OH, USA Search for more papers by this author Eung Jae Yoo Eung Jae Yoo Search for more papers by this author Nancy E Cooke Nancy E Cooke Search for more papers by this author Stephen A Liebhaber Corresponding Author Stephen A Liebhaber Search for more papers by this author Isabela Cajiao Isabela Cajiao Departments of Genetics and Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA Search for more papers by this author Aiwen Zhang Aiwen ZhangPresent address: Ohio State University, Columbus, OH, USA Search for more papers by this author Eung Jae Yoo Eung Jae Yoo Search for more papers by this author Nancy E Cooke Nancy E Cooke Search for more papers by this author Stephen A Liebhaber Corresponding Author Stephen A Liebhaber Search for more papers by this author Author Information Isabela Cajiao1, Aiwen Zhang, Eung Jae Yoo, Nancy E Cooke and Stephen A Liebhaber 1Departments of Genetics and Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA *Corresponding author. Department of Genetics, 428 Clinical Research Building, University of Pennsylvania, 415 Curie Blvd, Philadelphia, PA 19104, USA. Tel.: +1 215 898 7834; Fax: +1 215 573 5157; E-mail: [email protected] The EMBO Journal (2004)23:3854-3863https://doi.org/10.1038/sj.emboj.7600365 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Random assortment of genes within mammalian genomes establishes the potential for interference between neighboring genes with distinct transcriptional specificities. Long-range transcriptional controls further increase this potential. Exploring this problem is of fundamental importance to understanding gene regulation. In the human genome, the Igβ (CD79b) gene is situated between the pituitary-specific human growth hormone (hGH) gene and its locus control region (hGH LCR). Igβ protein is considered B-cell specific; its only known role is in B-cell receptor signaling. Unexpectedly, we found that hIgβ is transcribed at high levels in the pituitary. This Igβ transcription is dependent on pituitary-specific epigenetic modifications generated by the hGH LCR. In contrast, expression of Igβ at its native site in B cells is independent of hGH LCR activity. These studies demonstrated that a gene with tissue-restricted transcriptional determinants (B cell) can be robustly activated in an unrelated tissue (pituitary) due to fortuitous positioning within an active chromatin domain. This 'bystander' gene activation pathway impacts on current concepts of tissue specificity and models of active chromatin domains. Introduction Transcriptional controls in higher eukaryotes can be exerted over extended distances (Ptashne, 1986; Bresnick and Tze, 1997). Remote regulatory elements can function by establishing extensive 'activated' chromatin domains that encompass target promoters (Vyas et al, 1992; Hebbes et al, 1994; Bulger and Groudine, 1999; Elefant et al, 2000; Forsberg and Bresnick, 2001; Ho et al, 2002). Alternatively, remote regulatory elements can be brought into close juxtaposition with target promoters via long-range 'looping' or 'tracking' mechanisms (Mueller-Storm et al, 1989; Tewari et al, 1996; McDowell and Dean, 1999; Carter et al, 2002; Tolhuis et al, 2002). Sets of transcriptional regulatory determinants responsible for long-range gene activation pathways are generally referred to as locus control regions (LCRs) (Forrester et al, 1987; Grosveld et al, 1987). The identification of LCRs in a wide array of gene systems suggests that long-range transcriptional controls constitute common pathways for gene activation in higher eukaryotes. The extensive distances over which long-range controls can be exerted, and the close packing and random arrangement of many loci in the mammalian genome, establishes the potential for mutual interference among neighboring genes with distinct developmental or tissue specificities. Understanding how this significant problem in gene regulation is overcome is of fundamental importance. Insulator and boundary elements have been identified that can block a subset of such unwanted interactions (Chung et al, 1993; Hebbes et al, 1994; Bell and Felsenfeld, 1999). However, simple linear models of insulator/barrier function would be incompatible with effective insulation between loci with overlapping transcriptional control determinants. This suggests that more complex models of gene 'insulation' need to be formulated. Alternatively, certain loci may in fact not be fully insulated from the influence of unrelated transcriptional determinants and chromatin domains in their local environment. In this case, genes may be expressed in 'inappropriate' tissues or developmental settings. Such lack of precision in gene expression may be tolerated by the cell and/or might be compensated by post-transcriptional regulatory pathways. The human growth hormone (hGH) cluster contains five genes expressed specifically in the pituitary (hGH-N) or in the placenta (hCS-L, hCS-A, hGH-V, and hCS-B). The hGH LCR in these two tissues is composed of partially overlapping sets of HS. HSI and HSII are specific to pituitary chromatin, HSIV is specific to placental chromatin, while HSIII and HSV are formed in the chromatin of both tissues (Jones et al, 1995). The mechanism of long-range activation by the hGH LCR has been best defined in the pituitary. The two closely linked pituitary-specific HS, HSI and HSII, are situated 14.5–15.0 kb 5′ to the hGH-N promoter. These HS appear to recruit HAT activity with subsequent bidirectional spreading of histone acetylation (Elefant et al, 2000; Ho et al, 2002). These reactions establish a continuous 32 kb domain of acetylated chromatin that extends to encompass the hGH-N promoter. Epigenetic alterations within this domain are required for trans factor binding at the hGH-N promoter and for effective hGH-N transcriptional activation (Ho et al, 2002). Targeted inactivation of HSI results in loss of the acetylated histone domain in pituitary chromatin and is accompanied by 90–95% loss of hGH-N transgene expression (Ho et al, 2002). Thus hGH-N transcriptional activation and the establishment of the extensively modified hGH LCR chromatin domain are intimately linked processes and both are dependent on the function of HSI. The human CD79b/Igβ gene (referred to throughout as hIgβ) functions specifically in B lymphocytes (Hermanson et al, 1988). Igβ proteins form heterodimers with Igα to create the signal transduction subunit of the B-cell receptor (Campbell et al, 1991; Clark et al, 1992). As such, Igβ plays a critical and nonredundant role in B-cell differentiation and function (Papavasiliou et al, 1995). There are no additional functions defined for this protein. Considering this B-cell specificity, it is interesting and potentially problematic that the hIgβ gene is situated between HSI of the hGH LCR and the hGH-N promoter (Bennani-Baïti et al, 1998a, 1998b). This organization places the hIgβ locus within a hyperacetylated hGH LCR chromatin domain in somatotrope nuclei. The close packing of the hGH-N, hIgβ, and the hGH LCR thus presents a complex and potentially informative model to study mechanisms by which genes are shielded from each other's transcriptional control elements. In the present study, we report the unexpected observation that hIgβ is actively transcribed in the pituitary. Interestingly, activation of the hIgβ locus in the pituitary occurs in the absence of B-cell-specific transcription factors required for hIgβ expression in B cells. This activation of hIgβ in the pituitary reflects its fortuitous positioning within the activated chromatin domain generated by the hGH LCR. Thus, hIgβ is not shielded from the hGH LCR as might be expected, but instead is robustly activated by it. This 'bystander' gene activation may represent a relatively common phenomenon. As such it would have important implications for models of developmental and tissue-specific gene regulation within the mammalian genome. Results An hIgβ transgene with extensive flanking regions is appropriately expressed in mouse B cells The five genes within the hGH cluster are activated in either pituitary or placenta. In both situations, this activation is dependent on the action of a set of remote 5′ hGH LCR elements (Introduction). The B-cell-specific hIgβ gene is situated between the hGH LCR and the hGH cluster. We sought to identify a separate set of chromatin determinants in this region that were responsible for activation of hIgβ in B cells. Defining such determinants would allow us to model inter-relationships of transcriptional control elements within this tightly packed region of the genome. As an initial step, we assessed the expression of hIgβ from the 87 kb hGH/P1 transgene (Figure 1A). This previously described transgene (Su et al, 2000) contains hIgβ along with extensive flanking sequences. The flanking sequences include 31 kb of 5′-flanking sequences encompassing the entire hGH LCR and extending into the striated muscle-specific SCN4A gene and 51 kb of 3′-flanking sequences that contain hGH-N and three of the four placentally expressed genes of the hGH gene cluster. The expression of hIgβ from the hGH/P1 transgene was compared to that of the endogenous mouse (m) Igβ (Figure 1B). hIgβ was robustly expressed in the spleens of four hGH/P1 transgenic mouse lines. Expression per transgene copy was maintained within a two-fold range, varying from 25 to 42% of endogenous mIgβ. Immunofluorescent analysis of transgenic spleens confirmed that hIgβ protein expression was restricted to the B-cell compartment (Figure 1C). B-cell specificity was further substantiated by flow sorting of splenocytes (data not shown). These results indicated that the hGH/P1 transgene contains determinants sufficient to establish an autonomous, site-of-integration-independent chromatin environment that supports robust expression of hIgβ in mouse B cells. Figure 1.hIgβ expression in the spleens of hGH/P1 transgenic mice. (A) Map of the hIgβ/hGH locus and the hGH/P1 transgene. Each gene is represented by a labeled box. SCN4A, hIgβ, and the five genes in the hGH cluster are represented. The horizontal arrow above the locus indicates the hGH/P1 transgene. DNaseI HS of the hGH LCR are indicated by upward arrows along with their respective tissue specificities. (B) Splenic expression of hIgβ from the hGH/P1 transgene is copy number dependent. hIgβ mRNA and endogenous mIgβ mRNA were coamplified (RT/PCR) and the cDNAs were distinguished by restriction analysis. A representative RT/PCR analysis is presented in the autoradiograph and a diagram of the assay is shown below. The 5′ primer was 32P-end labeled and the PCR products were digested with HinfI (H) that exclusively digests the mIgβ PCR product and SfcI (S) that exclusively digests the hIgβ PCR product. The 5′-labeled fragments generated from mouse (63 bp) and human Igβ (95 bp) cDNAs are indicated (arrowheads). These signals were quantified from four unique hGH/P1 transgenic lines. The transgene copy number for each line is noted below each lane. Transgene expression per transgene copy was normalized to endogenous mIgβ and values are indicated as percentages below each respective lane. (C) hIgβ transgene is selectively expressed in the white pulp of the mouse spleen. (Left) Hematoxylin and eosin staining of an hGH/P1 transgenic spleen showing normal architecture of the spleen and indicating the defined areas of red pulp (rp) and white pulp (wp). (Middle) hGH/P1 transgenic spleen stained with anti-hIgβ (Texas red). The intense hIgβ staining is restricted to white pulp (wp) consistent with the local abundance of B lymphocytes. (Right) Nontransgenic, wild-type (WT) spleen stained with anti-hIgβ. The absence of a signal confirms the species specificity of the anti-hIgβ antibody. Download figure Download PowerPoint hIgβ transgene is expressed in the mouse pituitary The fidelity of hIgβ expression from the hGH/P1 transgene was evaluated by a tissue survey (Figure 2A). As expected, the spleen contained high levels of hIgβ and mIgβ mRNAs. In contrast, these mRNAs were at or below trace levels in the brain, heart, kidney, and liver, and at a slightly higher level in the intestine. Surprisingly, a strong hIgβ mRNA signal was detected in the pituitary. While an exact quantitative comparison of hIgβ mRNA levels in B cells and somatotropes is complicated by the presence of mixed cell populations in the spleen and pituitary, it was clear that the hIgβ mRNA level in the pituitary was robust, approximating that in the spleen. Figure 2.Igβ is transcribed from the hGH/P1 transgene in the mouse pituitary. (A) Tissue survey of hGH/P1 transgenic mice revealed abundant hIgβ mRNA in the pituitary. A co-RT/PCR endonuclease cleavage assay was used to analyze the tissue specificity of hIgβ expression in a representative hGH/P1 transgenic mouse line (line 809F). The RT/PCR assay was identical to Figure 1B with the exception that the 3′ primer is 32P-end labeled. The figure shows the PCR products digested with SfcI; the larger band (336 bp) corresponds to mIgβ and the smaller (250 bp) to hIgβ (labeled arrows). A separate RT/PCR of mIgα mRNA was carried out to monitor B-lymphocyte contamination in each tissue. The levels of hIgβ, mIgβ, and mIgα are shown relative to a β-actin mRNA loading control (ethidium bromide-stained gel). (B) Pituitary expression of hIgβ mRNA from the hGH/P1 transgene was copy number dependent. Pituitaries from four hGH/P1 transgenic mouse lines were assayed by RT/PCR for hIgβ mRNA. The level of hIgβ mRNA was normalized to endogenous mouse pituitary Igβ mRNA and this value is shown as a percentage below each pair of lanes after correction for gene copy number. Download figure Download PowerPoint Analysis of all four hGH/P1 transgenic lines confirmed the robust expression of hIgβ mRNA in the pituitary. These studies further revealed that the pituitary expression was copy number dependent, varying by less than three-fold (Figure 2B and real-time RT/PCR analysis, data not shown). Consistent with the expression of the hIgβ transgene in the pituitary, we also detected the endogenous mIgβ mRNA in this tissue, although at significantly lower levels. To address the possibility that hIgβ mRNA in transgenic mouse pituitary might reflect B-cell contamination, we assayed for mIgα mRNA (Figure 2A). Igβ and Igα are encoded on separate chromosomes in both human and mouse genomes (Campbell et al, 1991; Clark et al, 1992). As expected, mIgα mRNA was easily detected in transgenic mouse splenic RNA. However, mIgα mRNA was absent in the pituitary RNA samples, and could not be detected in any of the other surveyed transgenic tissues (Figure 2A). We concluded that the hIgβ gene is robustly transcribed in the transgenic mouse pituitary. The overall structure of hIgβ mRNA in transgenic pituitary is very similar to that in B cells The structure of the hIgβ transcripts in the pituitary was assessed. We considered two possible origins for the pituitary hIgβ transcripts that would differentiate them from authentic (B cell) Igβ mRNAs. First, these transcripts could represent noncoding (intergenic) RNAs randomly generated from the active hGH LCR chromatin domain. Intergenic transcription has been described throughout the human β-globin LCR (Ashe et al, 1997; Routledge and Proudfoot, 2002) and it has been implicated in chromatin modification (Gribnau et al, 2000). Second, hIgβ may be transcribed in the pituitary from an alternative promoter distinct from that used in B cells. To address these possibilities, hIgβ mRNA size was analyzed by Northern blotting. These data revealed that hIgβ mRNA in transgenic mouse pituitaries was of the same size as in transgenic mouse purified lymphocytes and human B cells (Figure 3A). The normal size of the pituitary hIgβ mRNA was incompatible with its generation by random transcription within the LCR domain. Figure 3.Structural comparison of hIgβ mRNAs in the transgenic pituitary and B cells. (A) Northern blot analysis. Total RNAs from a human B-cell line (1484), from wild-type (WT) mouse lymphocytes (spleen) and pituitary, and lymphocytes (spleen) and pituitary of hGH/P1 transgenic mouse line 809F were hybridized with a [32P] labeled hIgβ cDNA probe. The gel was stained with ethidium bromide to visualize 18S and 28S rRNAs as loading control. The hIgβ mRNA hybridizing bands comigrated in all tissues. No additional bands were detected. The absence of signal in the lanes containing WT lymphocytes and pituitary RNA confirmed the species specificity of the hIgβ probe. (B) Mapping the 5′ terminus of pituitary and B-cell Igβ mRNAs. The sequence of the hIgβ 5′-flanking region and 5′-terminal transcribed region are shown; the translation start site, ATG, is boxed. The 5′ termini of the transcribed mRNAs in B cells and transgenic pituitary were determined by 5′ RACE. The arrowheads indicate transcription start sites of hIgβ in the hGH/P1 transgenic mouse pituitary mRNA population. The dots indicate the hIgβ start sites in human B-cell line 1484. The figure also indicates the locations of the primers used for the 5′-RACE assay (dashed arrows) and the positions of introns 1 and 2. Download figure Download PowerPoint To determine whether the pituitary and B-cell hIgβ mRNAs begin at different promoters, the structures of their respective 5′ termini were determined by 5′ rapid amplification of cDNA ends (5′ RACE). hIgβ mRNAs isolated from the hGH/P1 transgenic pituitary and human B-cell line revealed multiple transcription initiation sites distributed across an overlapping 160-nucleotide window (Figure 3B). This scattering of 5′ termini is consistent with a previous study (Thompson et al, 1996) and with the TATA-less/GC-rich structure of the hIgβ promoter (Geng and Johnson, 1993; Donohoe and Blomberg, 1997; Dong et al, 2000). Of particular note, the 5′-terminal sequences in the 14 randomly selected pituitary hIgβ cDNAs were continuous with the genomic sequence encompassing exon 1 of the hIgβ gene. These data argued against the initiation of transcription from an alternative promoter/exon. The 5′-RACE sequence data also showed that pituitary hIgβ is normally spliced across intron 1. The correct size of the hIgβ RT–PCR product extending between exons 5 and 6 (see Figure 1B) confirmed that hIgβ pituitary mRNA was also correctly spliced across intron 5. Thus, on the basis of a number of structural parameters, we concluded that the hIgβ mRNA in the pituitary is closely related, if not identical, to the mature, authentic B-cell hIgβ mRNA. Igβ mRNA is expressed in the human pituitary We next considered whether the unexpected expression of hIgβ mRNA in the mouse pituitary reflected a peculiarity of the transgenic model. PolyA-primed cDNA was generated from normal human pituitary and from two human pituitary somatotrope adenomas (Figure 4). Controls for this study included mRNA samples from a transgenic pituitary, from human peripheral blood leukocytes (PBLs), and from a human erythroid cell line (K562). The identity of the pituitary samples was confirmed by the presence of hGH mRNA. hIgβ mRNA was detected in all three human pituitary samples in the absence of hIgα mRNA. In contrast, the control PBLs contained both hIgβ and hIgα mRNAs but neither was detected in K562 cells. The relative levels of hIgβ mRNA and hGH mRNA were similar in a comparison of the normal pituitary and pituitary adenoma #361. This comparison, however, revealed a relatively higher level of hGH mRNA in adenoma #373. This variation between the two adenomas may reflect the enrichment for somatotropes within the surgical samples or be a peculiarity of the adenoma pathology. This was not further explored. From these data we concluded that the transcription of hIgβ from the hGH/P1 transgene in the mouse pituitary faithfully recapitulated the expression of hIgβ in primary human pituitary tissues. Figure 4.hIgβ mRNA is expressed in human pituitaries. (Top panel) A normal human pituitary and two human pituitary adenomas (#361 and #373) were evaluated for hIgβ mRNA by RT/PCR using 32P-labeled RT–PCR primers. Positive controls were human peripheral blood lymphocytes (PBLs), hGH/P1 transgenic pituitary (809F line), and the negative control was the human erythroid cell line K562. (Second panel) Igα was monitored by RT/PCR with labeled primers. (Third panel) hGH RT/PCR with labeled primers identified the human and transgenic mouse pituitaries. (Bottom panel) Detection of m/hGAPDH by RT–PCR represented the loading control (ethidium bromide-stained products). All RT/PCR reactions were assayed in the linear range of amplification. Download figure Download PowerPoint hIgβ transcription in the pituitary is activated by the hGH LCR Igβ expression in B cells has been shown to reflect the activities of B-cell-specific transcription factors (Omori and Wall, 1993; Thompson et al, 1996; Akerblad et al, 1999). Therefore, the expression of hIgβ in the pituitary is likely to reflect an alternative pathway of gene activation. We speculated that this alternative mode of activation might reflect the localization of the hIgβ gene within the chromatin domain established in the pituitary by the hGH LCR. HSI of the hGH LCR has a unique and necessary role in establishing this activated chromatin domain (Introduction). We generated a series of transgenic lines carrying the hIgβ gene flanked by native sequences that either included (−8.0Igβ transgene) or excluded HSI (−1.3Igβ transgene and −0.2Igβ transgene) (Figure 5A). A semiquantitative co-RT/PCR assay was used to assess hIgβ mRNA levels in the pituitaries from mice representing three or more independent lines carrying each of the three hIgβ transgenes. hIgβ mRNA was robustly expressed from the transgenes containing HSI (−8.0Igβ). In contrast, hIgβ mRNA expression was dramatically lower in mice carrying transgenes truncated 3′ to HSI (−1.3Igβ and −0.2Igβ) (Figure 5B, left). hIgβ mRNA levels in representative lines were separately assessed by real-time PCR and normalized to endogenous mouse GAPDH mRNA (data not shown, see Materials and methods). The two sets of mRNA assays were in full agreement. These data support the central role of HSI in activating hIgβ transcription in the pituitary. Figure 5.hIgβ expression in the transgenic pituitary is dependent on the hGH LCR. (A) Transgene constructs. A map of the hGH gene cluster is shown. Horizontal arrows above the map indicate the extent of each transgene. The sizes of the constructs are indicated in parentheses and the designation of each construct indicates the extent of sequences 5′ from the hIgβ gene promoter. Note that hGH/P1 and −8.0Igβ transgenes include HSI whereas this determinant is excluded from the −0.2Igβ and −1.3Igβ transgenes. In hGH/P1(ΔHSI), a 99 bp segment (dashed box), corresponding to the critical core elements of HSI, has been deleted from the hGH/P1 transgene (Ho 2002). (B) HSI of the hGH LCR is a critical determinant of pituitary hIgβ expression. The ratios of pituitary hIgβ to mIgβ mRNAs in the series of hIgβ transgenic mouse lines (A) are shown. Mice from F1 or later generations and from at least three independent lines (dots) were analyzed (X-axis). The hIgβ to mIgβ mRNA ratios in each transgenic pituitary were plotted on the Y-axis as a percentage. The horizontal lines represent the mean values for each construct in the three or more lines analyzed. Representative co-RT/PCR endonuclease cleavage assays corresponding to each construct are shown below the graph. Wild-type mouse (WT) pituitary RNA was used as negative control. Expression ratios were corrected for transgene copy number. Download figure Download PowerPoint The involvement of HSI in the activation of hIgβ in the pituitary was further tested by a second approach. Deletion of a core 99 bp segment of HSI (hGH/P1ΔHSI transgene; see Figure 5A) destroys HSI formation, dramatically decreases acetylation throughout the hGH LCR, and results in a 20- to 40-fold decrease in hGH-N transgene expression (Ho et al, 2002). The impact of HSI on hIgβ transcription was tested by comparing levels of hIgβ mRNA in the pituitaries of lines carrying the intact hGH/P1 transgene to lines carrying the inactivated HSI (hGH/P1ΔHSI). This comparison revealed a mean 47-fold decrease in hIgβ mRNA in the lines lacking a functional HSI (Figure 5B, right). The data were confirmed by independent real-time PCR analysis of hIgβ mRNAs in representative lines (data not shown). Thus, the activation of pituitary hIgβ transcription was dependent on HSI, the major hGH LCR determinant in the pituitary. Expression of hIgβ in B cells is independent of hGH LCR action The formation of HSI of the hGH LCR is specific to the pituitary (Jones et al, 1995) and hGH-N mRNA is not found in the spleen (Figure 6A). Despite this tissue specificity of hGH LCR function, the pronounced effect of HSI on hIgβ expression in the pituitary prompted us to formally test whether HSI enhances hIgβ expression in B cells. Comparison of hIgβ mRNA levels in the spleens of hGH/P1 and hGH/P1(ΔHSI) mice revealed equally robust and copy number-dependent levels from both transgenes (Figure 6B; compare with Figure 1B). These data are consistent with the tissue specificity of hGH LCR function and support the conclusion that HSI activates hIgβ transcription in the pituitary but has no appreciable function in the B-cell chromatin context. Figure 6.Activation of hIgβ transcription by the hGH LCR is limited to the pituitary. (A) hGH-N mRNA is restricted to the pituitary. mGH and hGH mRNAs were detected by an RT/PCR endonuclease cleavage assay. This assay, shown below the autoradiograph, was applied to tissues from an hGH/P1 transgenic mouse. Arrows to the left of the autoradiograph (upper panel) indicate the expected positions of the mGH and hGH RT/PCR products. In the lower panel, β-actin PCR products in each lane are visualized by ethidium bromide staining. (B) hIgβ transgene expression in the spleen is not linked to HSI activity. Splenic RNA samples from three independent lines of mice carrying the hGH/P1ΔHSI construct (lines 960G, 961E, and 969E) were analyzed for hIgβ expression by the co-RT/PCR endonuclease cleavage assay (Figure 1B). The level of transgene expression per gene copy was determined. The percentage of hIgβ to endogenous mIgβ expression is indicated below the autoradiograph. (C) hIgβ is not expressed in the placenta. RNA samples from an hGH/P1 placenta (line 809C), a human term placenta, a transgenic pituitary, human PBLs, and an erythroid cell line (K562) were each analyzed for hIgβ expression by RT/PCR. Igα mRNA was assessed to detect potential B-cell contamination of the tissue samples. The lower panel visualizes the products of a β-actin RT/PCR assay by ethidium bromide staining shown as a loading control. Download figure Download PowerPoint hIgβ is not activated by the hGH LCR in the placenta The hGH LCR activates expression of pituitary and placental genes from the hGH cluster via distinct epigenetic pathways. In the pituitary, the LCR establishes a continuous 32 kb domain of acetylated chromatin (Elefant et al, 2000; Ho et al, 2002). In contrast, acetylation of the LCR and the GH genes in placental chromatin is highly localized to two discontinuous regions, HSV–HSIII region and the region encompassing the four closely linked placental genes within the cluster (Kimura et al, 2004). Of particular note, levels of histone H3 and H4 acetylation in the region encompassing hIgβ (between HSIII and the hGH gene cluster) are quite low in placental chromatin when compared to the pituitary. The dependence of hIgβ gene activation in the pituitary on its positioning within a highly acetylated chromatin domain could therefore be further addressed by analyzing hIgβ expression in the placenta. In comparison to the robust expression of hIgβ mRNA in the transgenic pituitary and human B cells, hIgβ mRNA in the placental samples could only be detected at trace levels (Figure 6C and data not shown). These data support the conclusion that activation of hIgβ is directly related to its location within the highly acetylated LCR chromatin domain formed in the pituitary. hIgβ mRNA in the pituitary is not effectively expressed at the protein level The presence of hIgβ mRNA in the pituitary suggested that hIgβ protein might be synthesized at this site. hIgβ protein could theoretically contribute to a novel somatotrope signaling complex. hIgβ protein expression was therefore assessed by Western analysis of transgenic pituitary extracts. A strong hIgβ signal was detected in the transgenic spleen extracts and human B-cell extracts. In contrast, the Western blots failed to reveal convincing evidence for hIgβ in the pituitary (Figure 7). Immunofluorescent microscopy was carried out using hGH/P1 transgenic pituitaries. These studies were essentially negative with only a rare cell showing evidence of positive hIgβ staining (data not shown). We concluded that the abundant hIgβ mRNA in the pituitary is either poorly translated or hIgβ protein, once synthesized, is rapidly catabolized due to the lack of a partneri
Referência(s)